Immune interferon (IFN-y) increases the surface expression of HLA-A,B antigens and induces the surface expression of HLA-DR antigens on vascular endothelial cells and dermal fibroblasts. Here we report that IFN-y induces parallel expression of two other class H major histocompatibility complex (MHC) antigens, SB and DC. Maximal surface expression of all three antigens is reached in 4-6 days, and HLA-DR and -SB are induced to a higher level of expression than HLA-DC. For all three class II antigens, induction is marked by the de novo appearance of detectable transcripts of class II heavy and light chains and of the non-MHC-encoded invariant chain, suggestive of the transcription of multiple previously silent genes. Class I message levels and antigen expression are also increased by IFN-y at similar rates but from initial levels that are 50% of maximal. After removal of IFN-y, class II antigen expression persists for at least 4 days, while mRNA levels decrease rapidly. The parallel induction and persistence of the several class II MHC antigens may be important in conferring immune accessory function on vascular and stromal cells. 8) .
face expression of all three antigens is reached in 4-6 days, and HLA-DR and -SB are induced to a higher level of expression than HLA-DC. For all three class II antigens, induction is marked by the de novo appearance of detectable transcripts of class II heavy and light chains and of the non-MHC-encoded invariant chain, suggestive of the transcription of multiple previously silent genes. Class I message levels and antigen expression are also increased by IFN-y at similar rates but from initial levels that are 50% of maximal. After removal of IFN-y, class II antigen expression persists for at least 4 days, while mRNA levels decrease rapidly. The parallel induction and persistence of the several class II MHC antigens may be important in conferring immune accessory function on vascular and stromal cells.
The class II antigens of the major histocompatibility complex (MHC) are products of the immune response genes (1) and serve as restriction elements in antigen presentation to T lymphocytes (2)-i.e., T-helper cells only recognize nominal antigen in combination with the polymorphic determinants of a self-class II MHC antigen. Traditionally, it was thought that only cells of the immune system express cell-surface class II molecules (3, 4) . In addition, class II antigens on cells of the monocyte-macrophage line and their tumors could be increased or induced by immune interferon (IFN-y) (reviewed in ref. 5 ). On murine macrophages, the expression of class II antigens is a transient event and may regulate the ability of these cells to interact with T cells (5, 6) . Unexpectedly, HLA-DR, the best characterized human class II antigen, could also be induced on human umbilical vein endothelial cells (HUVE) and human dermal fibroblasts (HDF) by recombinant IFN-y (7, 8) .
To date, three sets of human class II antigens (HLA-DR, -DC, and -SB) have been identified. All three sets of antigens have been studied at the protein and nucleic acid level; they consist of similar heterodimers with heavy chains of --34 kDa, and light chains of "-29 kDa (1). Biosynthetic intermediates, but not mature surface-expressed class II antigens, appear associated with a non-MHC non-polymorphic "invariant" chain of ==31 kDa (9) . In human, but not in murine cells, class II MHC loci may be independently expressed (10) (11) (12) . Furthermore, differential expression (e.g., DR', DC-) may be correlated with limitations on the ability of the class II antigen-bearing cell to interact with responding T cells (10) (11) (12) . To understand more fully the potential of endothelial and stromal cells to interact with T cells, the effects of IFN-y on these cells have been studied in greater detail, and it has been found that: (i) recombinant human IFN-y induces the de novo appearance of transcripts of multiple class II antigen genes, including the a and f3 genes of HLA-DR, -DC, and -SB, as well as transcripts of the invariant (-y) chain, with subsequent surface expression of all three class II antigens; and (il) after removal of IFN, the class II-specific mRNAs disappear relatively rapidly, while the antigens remained expressed on the surface at relatively constant levels for several days.
MATERIALS AND METHODS
HUVE cells were isolated and grown in primary culture as described (13) . In some experiments, HUVE cells were passaged (5-10 subcultures) in medium containing 100 Ag of endothelial cell growth factor per ml (a generous gift of Thomas Maciag, Meloy Laboratories, Springfield, VA) and porcine heparin (Sigma) on 0.1% gelatin-coated (Difco) dishes (14) . HDF (a generous gift of James Rheinwald, Dana-Farber Cancer Institute, Boston; see ref. 15 ) strains were cultured as described (8) . HUVE and HDF cultures were treated where indicated with IFN-y by addition of 0.1% (vol/vol) medium conditioned by a transfected Chinese hamster ovary fibroblast line [final IFN activity, 100 units/ml (16) ].
The monoclonal antibodies reacting with MHC antigens are listed in Table 1 . Monoclonal antibody binding measurements and fluorescence flow cytometry were carried out with HUVE and HDF cells as described (7, 24) .
Total cytoplasmic RNA was prepared as described by Maniatis et al. (25) . Denatured total cytoplasmic RNA and poly(A)+ RNA from the B lymphoblastoid cell line LB (26) was electrophoresed in a formaldehyde-containing 1% agarose gel, transferred to nitrocellulose, and probed with nicktranslated cDNA inserts, as described (25) . RNA 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. were treated with or without IFN-y for 5 days and monoclonal antibody binding to confluent monolayers was quantified as described (8) . Nonspecific binding (2.8 ± 0.3 x 10-3 cpm) was measured using UPC 10, a mouse myeloma protein, and subtracted. All values are means of triplicate determinations and represent specific binding, cpm x 10-3 per well ± SD.
Cross-hybridization was observed between DCa and DRa only above 2x NaCl/Cit (27) . Blots were autoradiographed using XAR-5 film (Kodak) and intensifying screens, and the intensity of mRNA bands from autoradiograms was measured with a Quick Scan densitometer (Helena Laboratories, Beaumont, TX) working within the linear range of the film.
The cDNA probes used include DRa [an 1100-base-pair (bp) Pst I partial fragment of pDRa-15 (28) passaged HUVE and two strains of HDF. The identified mRNAs were -1400 nucleotides and comigrated with the mRNA bands detected in 250 ng of poly(A)+ RNA from a Blymphoblastoid line (LB; DRw6,6). Neither a-nor /chain HLA-DR mRNAs were detected in untreated HUVE or HDF preparations. Similarly, DCa-, DC/3, SBa-, and SB3-specific probes detected mRNAs present in all the IFN treated cultures but not in controls (Fig. 1) . Transcripts of invariant chain were also detected in IFN-treated but not in untreated HUVE and HDF cells (Fig. 1) .
Three points deserve further comment. (i) Two sizes of DCa-specific mRNAs were observed of 1100 and 1300 nucleotides (Fig. 1) . The DCa-chain genes are polymorphic [and correlated with the serologically defined MT1 (DC1), MT2 (DC3), and MT3 (DC4) specificities in linkage disequilibrium with DR1,2,6; DR3,5,6,8; and DR4,7, respectively]. Sequences of the DC1a and DC4a cDNAs have revealed that the former mRNA is 1% nucleotides larger than the latter as the result of the use of different splice sites for the exons encoding the 3' untranslated regions (30, 34) ; DC3a also encodes the larger 1300-bp mRNA (34) . Thus, HUVE (derived from multiple pooled donors) contained both sizes of DCa mRNA, while HDF-1 (from a DR7,-, thus DC4 donor) had only the 1100-bp mRNA and HDF-5 (from a DR5,6, thus either DC3,3 or DC1,3) had only the 1300-bp mRNA. These results confirm the specificity of the DCa-chain probe used.
(ii) Cross-hybridization between induced mRNA species for HLA-DRa and -/3 chains and the full length HLA-SB and DCa-and DC,/chain cDNA probes cannot explain the observed induction of HLA-SB and -DC transcripts. Probes specific for the 3' untranslated regions of several genes with low sequence homology to other genes were generated. Such probes for SBa (HB20: Pst/Bgl II fragment), SB/3 (pHAB-10-DD2: Sac I/HindIII fragment), and DC/3 (p2/31: Pvu II fragment) detected transcripts of the same size as the fulllength cDNA probes under high stringency (data not shown). Small differences in size (-100 nucleotides) between the induced class II a-and /-chain transcripts and invariant chain with the corresponding B-cell transcripts may result from slight electrophoretic mobility differences on these denaturing gels between purified B-cell poly(A)+ RNA used as the reference and total cytoplasmic RNA from HUVE and HDF.
(iii) The invariant chain probe identified an abundant 1400-nucleotide transcript from the B-lymphoblastoid line poly(A)+ RNA; however, in both HDF strains and passaged HUVE, the cDNA probe identified two mRNAs: a major species of -1400 nucleotides and a minor larger species of -1500 nucleotides. Previous work with a similar clone (35) found that in some B-cell lines, in addition to the 1400-nucleotide RNA, the cDNA probe hybridized to a larger (1800 nucleotide) minor species. /32 microglobulin, another nonpolymorphic protein associated with MHC antigens, has also been noted to show multiple-sized transcripts, in this case resulting from use of alternative polyadenylylation sites (36) .
The Rate of MHC Class II mRNA Induction Is Faster Than Antigen Expression. The kinetics of class II antigen induction was monitored by examining both surface expression of HLA-DR and cytoplasmic mRNA content. After a 1-day lag period, surface expression of HLA-DR antigen, measured by the binding of a monomorphic monoclonal antibody (LB3.1), increased from an undetectable level to plateau values at 5-6 days (Fig. 2) . The percentage of HLA-DR positive cells in the population was determined by fluorescence-activated cell sorter (FACS). Binding of LB3.1 to HDF-5 in untreated cultures (Fig. 3a, large dots) is indistinguishable from nonspecific binding with a mouse myeloma protein (Fig. 3a , small dots). After 2 days of IFN-y treatment, the entire population has become HLA-DR positive (Fig. 3b) , reaching a plateau value at 4-6 days (Fig. 3c) . Uniform induction of HLA-DC was also observed, although at a slower rate and to a lower final level.
mRNA levels for HLA-DRa chain, following IFN-y treatment, increased from undetectable levels to plateau values by 24-48 hr (Fig. 2) . Since the amount of total mRNA present in the cytoplasmic RNA sample and the lymphoblastoid poly(A)+ RNA are approximately equivalent (250 ng), relative abundance can be assessed by direct comparison. Blots were reprobed with a tubulin cDNA, confirming that equivalent amounts of mRNA were transferred to each lane (data not shown). HLA-DR is estimated to comprise 0.01%-0.05% of total mRNA in B cells (33, 37) . In the IFN-y-treated samples, HLA-DR mRNA becomes as abundant as found in the B-cell line and remains at that level during the course of IFN-y treatment. The plateau value of HLA-DR mRNA content preceded maximal surface expression of the antigen by 1-2 days. HLA-DCa-chain mRNA appeared to be expressed at lower levels during IFN-y treatment. The rate of appearance of invariant chain mRNA (Fig. 2) exactly paralleled that of HLA-DRa-chain mRNA.
In contrast to the class II induction, surface expression of a class I antigen measured with a monomorphic monoclonal antibody (W6/32) increased linearly to plateau values 1.5-to 2.5-fold greater than controls at 3-4 days after treatment (Fig. 2) . By FACS analysis, each cell expressed more HLA-A,B, accounting for the increase. The class I a-chain probe detected a single 1700-nucleotide transcript in cytoplasmic RNA from HDF and HUVE, which comigrated with the mRNA identified in B-cell poly(A)+ RNA. Class I mRNA increased 3.5-fold during 1 day of treatment, and it increased 6-fold over untreated samples by day 3. This increase in class I mRNA level exceeds the 2-fold increase of class I antigen expressed on the cell surface. Class II mRNA but Not Antigen Expression Rapidly Declines After IFN-y Withdrawal. Both class I and class II antigen surface expression were relatively stable during the first 2 days after withdrawal of IFN-y, as measured by a surface antibody-binding assay (Fig. 4) . After 4 days in the absence of IFN-y, HLA-DR surface expression had decreased 32% and HLA-A,B decreased 64%. FACS analysis showed that the entire cell population lost small amounts of antigen at the same rate ( Fig. 3 ; data not shown for class I). By contrast, HLA-DR, -DC, -SBa-chain, and invariant mRNA levels decreased to minimally detectable levels during 4 days in the absence of IFN-y. Similarly, expression of class I antigen at the surface decreased by a factor of about 2 during 4 days in the absence of IFN-y, while mRNA levels decreased by a factor of at least 5.
DISCUSSION
In the present study, recombinant IFN-y has been used to study the mechanism of MHC antigen regulation in cultured vascular endothelial cells and stromal fibroblasts. IFN-y increases class I mRNA levels in B-lymphoblastoid cells at concentrations far lower than those needed to induce the antiviral state (38) . In this study, we confirm that IFN-y increases class I mRNA expression, but the rates of surface expression on vascular endothelial cells and dermal fibroblasts are slower than that previously reported for lymphoblastoid cells and foreskin fibroblasts (39) or in murine L cells transfected with a human class I gene (40 
